Journal of Radiopharmaceuticals and Molecular Probes (대한방사성의약품학회지)

Korean Society of Radiopharmaceuticals and Molecular Probes (대한방사성의약품학회)
권호 표지
DOI QR코드

DOI QR Code

Consideration of the benefits of using a high current accelerator in BNCT

  • Cho, Ilsung (Department of Korea Institute of Radiological & Medical Sciences) ;
  • Min, Sun-Hong (Department of Korea Institute of Radiological & Medical Sciences) ;
  • Park, Chawon (Department of Korea Institute of Radiological & Medical Sciences) ;
  • Kim, Minho (Department of Korea Institute of Radiological & Medical Sciences) ;
  • Lee, Kyo Chul (Department of Korea Institute of Radiological & Medical Sciences) ;
  • Lee, Yong Jin (Department of Korea Institute of Radiological & Medical Sciences) ;
  • Hong, Bong Hwan (Department of Korea Institute of Radiological & Medical Sciences) ;
  • Lim, Sang Moo (Department of Korea Institute of Radiological & Medical Sciences)
  • Received : 2020.06.15
  • Accepted : 2020.06.26
  • Published : 2020.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Boron Neutron Capture Therapy (BNCT) has the advantage of selectively removing cancer cells ingesting boron compounds. In this study, the benefits for treatment time and boron compound injection dose were compared between current neutron sources and a high current neutron sources to be developed in near future. The time-activity curve (TAC) of GBM (Glioblastoma) for one bolus injection was obtained by applying modified 3 compartment model. The treatment time was determined for an accelerator-based neutron sources at the present time and a high current accelerator based neutron source to be developed in the near future. In the case of the double amount of IAEA-recommended neutron flux, the treatment time was shortened to 15 minutes. In the case of high current accelerators, which are five times the amount of IAEA-recommended neutron flux, the irradiation time is within 5 minutes. The use of a high current accelerator based neutron source in BNCT is advantageous in terms of treatment time. In addition, it can increase the efficiency of use of neutrons and reduce the boron compound injection dose to patients, thus reducing pharmacological toxicity.

Keywords

References

  1. INTERNATIONAL ATOMIC ENERGY AGENCY, Current Status of Neutron Capture Therapy, IAEATECDOC-1223, IAEA, Vienna (2001).
  2. 임상무, 홍봉환, 정원균, 박차원, 조일성, 민선홍, 이교철, 정해조. 가속기 기반 BNCT의 기술검토. 한국원자력의학원; 2019.
  3. 과학기술부 주관 원자력연구개발 중장기계획 보고서. 원자로를 이용한 붕소중성자포획치료법 개발. 한국원자력연구원; 2007.
  4. Yoshiaki K. Accelerator-based neutron source for boron neutron capture therapy. Ther Radiol Oncol 2018;2:55 https://doi.org/10.21037/tro.2018.10.05
  5. Andres JK, Javier B, Daniel C, Matias B, Walter C, Javier G, Javier P, Juan CSS, Marcelo I, Julian E, Daniel M, Alejandro AV, Daniel MM, Maria SH, Mariela FG, Leonardo G, Manuel SA, Nicolas C, Nicolas R, Marcelo G, Hernan T. Present status of Accelerator-Based BNCT. Rep Pract Oncol Radiother 2016;21:95-101 https://doi.org/10.1016/j.rpor.2014.11.004
  6. Blue TE, Yanch JC. Accelerator-based epithermal neutron sources for boron neutron capture therapy of brain tumors. J Neurooncol 2003;62;19-31
  7. Tanaka H, Sakurai Y, Suzuki M, Masunag S, Kinashi Y, Kashino G, Liu Y, Mitsumoto T, Yajima S, Tsutsui H, Maruhashi A, Ono K. Characteristics comparison between a cyclotron-based neutron source and KUR-HWNIF for boron neutron capture therapy. NIM B 2009;267;1970-1977 https://doi.org/10.1016/j.nimb.2009.03.095
  8. Taskaev S, Aleynik V, Burdakov A, Ivanov A, Kuznetsov A, Makarov A, Sorokin I. Vacuum-insulation tandem accelerator for boron neutron capture therapy. Proceedings of IPAC2011 2011;San Sebastian, Spain
  9. Fowler JF, Welsh JS, Howard SP. Loss of Biological effect in prolonged fraction delivery. Int J Radiat Oncol Biol Phys 2004;59(1):242-9. https://doi.org/10.1016/j.ijrobp.2004.01.004
  10. Imahori Y, Ueda S, Ohmori Y, Sakae K, Kusuki T, Kobayashi T, Takagaki M, Ono K, Ido T, Fujii R. Positron Emission tomography-based boron neutron capture therapy using boronophenlylalanine for high-grade glimoas: part I. Clin Cancer Res 1998;4:1825-32
  11. Hum BG, Daniel JM, John EB, Arthur LB. Validation of a dose-point kernel convolution technique for internal dosimetry Phys. Med. Biol. 1995:40:365 https://doi.org/10.1088/0031-9155/40/3/003